What do the ZAO and KOYA AI models do?

ZAO is a molecular evaluation model for high-accuracy prediction; KOYA is a generation model for designing novel drug candidates. Together, they accelerate early drug discovery.

How do these models integrate with NVIDIA?

They are accessible via NVIDIA BioNeMo Agent Toolkit, enabling AI agents to automatically perform molecular evaluation and design.

Has their effectiveness been proven in real drug discovery projects?

Yes, a joint virtual screening of 38 billion compounds with Enamine demonstrated up to 90% reduction in exploration costs.

How advanced is ZAO's performance?

ZAO achieved #1 rankings in 9 public TDC benchmarks without task-specific training, as of July 2026.

Can KOYA generate molecules superior to existing ligands?

Yes, in 8 out of 10 evaluated targets, KOYA generated novel molecules outperforming known binders in docking evaluations.

AI News NQ Analysis

SyntheticGestalt Launches Molecular AI Models 'ZAO' and 'KOYA'

NQ Score 97/100

N1 Content Completeness 10

AI Summary (NQ-processed)

SyntheticGestalt Inc. has launched two molecular AI foundation models, 'ZAO' and 'KOYA', designed to accelerate drug discovery and chemical R&D. The models integrate with NVIDIA BioNeMo Agent Toolkit, enabling AI-driven workflows.

AI Analysis

Frequently Asked Questions

Q: What do the ZAO and KOYA AI models do?: A: ZAO is a molecular evaluation model for high-accuracy prediction; KOYA is a generation model for designing novel drug candidates. Together, they accelerate early drug discovery.
Q: How do these models integrate with NVIDIA?: A: They are accessible via NVIDIA BioNeMo Agent Toolkit, enabling AI agents to automatically perform molecular evaluation and design.
Q: Has their effectiveness been proven in real drug discovery projects?: A: Yes, a joint virtual screening of 38 billion compounds with Enamine demonstrated up to 90% reduction in exploration costs.
Q: How advanced is ZAO's performance?: A: ZAO achieved #1 rankings in 9 public TDC benchmarks without task-specific training, as of July 2026.
Q: Can KOYA generate molecules superior to existing ligands?: A: Yes, in 8 out of 10 evaluated targets, KOYA generated novel molecules outperforming known binders in docking evaluations.